Nanoligent is a preclinical stage drug discovery company based in Barcelona. We are focused on METASTASIS as an unmet clinical need, developing precision medicines that selectively kill metastatic tumor cells. The therapeutic approach is the selective elimination of CXCR4 positive tumor cells. CXCR4 is a well-known therapeutic target in cancer, overexpressed in an extended subpopulation of patients (above 40%) and highly correlated with poor prognosis. We have an extraordinarily successful preclinical data and a robust IP portfolio protecting the technology to deliver drugs that can be applied to 23 metastatic cancer types, all overexpressing the CXCR4 receptor.
Our first drug in the pipeline is directed to metastatic colorectal cancer, as a first entry indication with a clear unmet need and a huge market. To complete a Phase II clinical trial, the company needs EUR 15M. Currently raising the first million as a bridge for a tranche of EUR 5M to achieve Clinical Trial Authorization.
Our first drug in the pipeline is directed to metastatic colorectal cancer, as a first entry indication with a clear unmet need and a huge market. To complete a Phase II clinical trial, the company needs EUR 15M. Currently raising the first million as a bridge for a tranche of EUR 5M to achieve Clinical Trial Authorization.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Spain
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
NNL121
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
